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Summary
 
The complete healing of wounds is the final step in a highly regulated response to injury. Al-
though many of the molecular mediators and cellular events of healing are known, their ma-
nipulation for the enhancement and acceleration of wound closure has not proven practical as
yet. We and others have established that adenosine is a potent regulator of the inflammatory re-
sponse, which is a component of wound healing. We now report that ligation of the G
 
a
 
s
 
-
linked adenosine receptors on the cells of an artificial wound dramatically alters the kinetics of
wound closure. Excisional wound closure in normal, healthy mice was significantly accelerated
by topical application of the specific A
 
2A
 
 receptor agonist CGS-21680 (50% closure by day 2 in
A
 
2
 
 receptor antagonists. In rats rendered diabetic (streptozotocin-induced diabetes mellitus)
wound healing was impaired as compared to nondiabetic rats; CGS-21680 significantly in-
creased the rate of wound healing in both nondiabetic and diabetic rats. Indeed, the rate of
wound healing in the CGS-21680–treated diabetic rats was greater than or equal to that ob-
served in untreated normal rats. These results appear to constitute the first evidence that a small
molecule, such as an adenosine receptor agonist, accelerates wound healing in both normal an-
imals and in animals with impaired wound healing.
 
W
 
ound healing is a complex process characterized by
three overlapping phases: inflammation, tissue for-
mation, and tissue remodeling. During tissue formation,
growth factors synthesized by local and migratory cells stim-
ulate fibroblasts to migrate into the wound where they pro-
liferate and construct an extracellular matrix. In response to
many of the same growth factors, keratinocytes migrate from
the edge of the wound over the surface of the injured area
and proliferate until the wound is completely covered. Both
matrix formation and epithelialization, in turn, depend upon
angiogenesis, a process that occurs through the migration,
proliferation, and organization of vascular endothelial cells.
Earlier studies demonstrated that a variety of peptide growth
factors may promote reepithelialization, migration of fibro-
blasts into a wound, and angiogenesis, but no small mole-
cules of potentially greater use have yet been shown to en-
hance the rate at which wounds close in normal healthy
animals (1).
Because of their potent effects on some of the cells in-
volved in wound healing, we hypothesized that adenosine
receptor agonists promote wound healing both in vitro and
in vivo. Previous studies have demonstrated that adenosine,
acting at A
 
2
 
 receptors, inhibits neutrophil accumulation and
function (2) and promotes endothelial cell proliferation,
migration, and secretion of growth factors (3–6). In con-
trast, adenosine receptor occupancy inhibits keratinocyte
proliferation (7) and its effects on fibroblast proliferation are
inconsistent (3, 8). Four adenosine receptors have been
cloned and the deduced sequences reveal that all four are
members of the large family of 7 transmembrane–spanning,
G protein–coupled receptors. Three of the adenosine re-
ceptor subtypes, A
 
1
 
, A
 
2A
 
, and A
 
2B
 
, are highly conserved
throughout evolution (80–95% sequence homology), whereas
the A
 
3
 
 receptors differ significantly among species (for re-
view see reference 9). Adenosine A
 
1
 
 and A
 
2
 
 receptors were
first differentiated by their opposing effects on cAMP accu-
mulation (10, 11), effects mirrored, in some cell types (e.g.,
neutrophils), by opposing functional effects (for review see
reference 2).
Because results of preliminary in vitro studies indicated that
adenosine A
 
2
 
 receptor agonists promoted fibroblast and en-
dothelial cell migration into an artificial wound, we tested
the effects of a specific adenosine A
 
2A
 
 receptor agonist, CGS-
21680 (4-[{
 
N
 
-ethyl-5
 
9
 
-carbamoyladenos-2-yl}aminoethyl]
phenylpropionic acid), on wound healing in normal mice
and rats and in rats rendered diabetic. We report here that
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adenosine, acting at specific A
 
2A
 
 receptors, promotes heal-
ing both in normal, healthy, young animals and in diabetic
animals with impaired wound healing.
 
Materials and Methods
 
Materials.
 
CGS-21680, DMPX (3,7-dimethyl-1-propargyl-
xanthine), and CSC (8-(3-chlorostyryl)caffeine) were obtained from
Research Biochemicals, Inc. (Natick, MA). Tissue culture media
and reagents were obtained from GIBCO BRL (Bethesda, MD).
 
Cell Lines.
 
Fibroblasts (CCD-25sk) were obtained from the
American Type Culture Collection (Rockville, MD) and were
originally derived from normal human dermal fibroblasts. These cells
were grown to confluence in standard tissue culture medium con-
sisting of MEM/10% fetal bovine serum (vol/vol). HUVEC were
obtained by modifications of the method of Jaffe et al. (12). In
brief, HUVEC were obtained by collagenase treatment of fresh
human umbilical cords and grown to confluence in medium 199
with 20% fetal bovine serum, antibiotics, and endothelial growth
supplement at 37
 
8
 
C in a 5% CO
 
2
 
 atmosphere (12, 13). The ex-
periments in the study were performed on HUVEC in their third
passage.
 
Reverse Transcriptase–PCR of Adenosine Receptor mRNA.
 
Total
RNA from confluent monolayers of either HUVEC or CCD-
25sk cells was isolated by the RNAzol
 
Ô
 
 B method (Tel-Test,
Inc., Friendswood, TX) and first-strand cDNA was synthesized by
GeneAmp
 
Ô
 
 RNA PCR Core Kit (Perkin-Elmer Corp., Branch-
burg, NJ) according to the directions. The amplification primers
for the adenosine receptor messages have been previously de-
scribed by Nilsen et al. (Nilsen, D., A. Talbot, C. Aston, R. Hirsch-
horn, B.N. Cronstein, and J. Reibman, manuscript submitted for
publication) and Boyle et al. (14). Upstream primers for the A
 
1
 
,
A
 
2A
 
 and the A
 
2B
 
 receptors were GGTGGAATTCTCCATCT-
CAGCTTTCCAGGC, GGTGGAATTCAACAACTGCGG-
TCAGCCAAA, and GGTGGAATTCGAACCACGAATGAA-
AGCTGC, respectively, and the downstream primers were
GGTGAAGCTTTCGAACTCGCACTTGATCAC, GGTGAA-
GCTTCAGCTGCCTTGAAAGGTTCT, and GGTGAAGCT-
TTGACCATTCCCACTCTTGAC, respectively. The nested
amplification primers for A
 
3
 
 receptors were AACGTGCTGGT-
CATCTGCGTGGTC (upstream), GTAGTCCATTCTCATG-
ACGGAAAC (downstream), and CTGCAGACCACCACCTT-
CTATTTC (nested). Template first-strand cDNA (150 ng) was
added to a reaction mixture which included dNTPs (0.2 mM
each), Mg
 
2
 
1
 
 (25 mM) and appropriate primers (1 mM), and 
 
Taq
 
DNA polymerase (0.025 U/
 
m
 
l) in a final volume of 50 
 
m
 
l. The
PCR was carried out in a thermocycler (GeneAmp 2400; Perkin-
Elmer) programmed as follows: 94
 
8
 
C (2 min), and then 35 cycles
of 94
 
8
 
C (1 min), 58
 
8
 
C (1 min), 72
 
8
 
C (3 min), followed by a 10-
min terminal extension (72
 
8
 
C) for the A
 
1
 
 receptor. The A
 
2A
 
, A
 
2B
 
,
and A
 
3
 
 receptors were amplified using the following program:
94
 
8
 
C (2 min), and then 35 cycles of 94
 
8
 
C (30 s), 58
 
8
 
C (30 s), and
72
 
8
 
C (45 s), followed by a 10-min terminal extension (72
 
8
 
C).
PCR products were separated in a 1.8% agarose gel. Sequencing
of the PCR products confirmed their identity with previously
described portions of the appropriate adenosine receptors.
 
Excisional Wound Formation.
 
Two sterile, full-thickness exci-
sional wounds (12 mm in diameter) were formed on the dorsum
of anesthetized 6–8-wk-old male and female mice (BALB/c) using a
template and scissors. Wounds were treated daily with topical ap-
plication of 20 
 
m
 
l of either the adenosine agonist CGS-21680
(250 
 
m
 
g/ml) or vehicle (1.5%, wt/vol carboxymethylcellulose in
PBS) in the presence or absence of either the adenosine receptor
antagonist DMPX (2.5 mg/ml) or CSC (250 
 
m
 
g/ml). Mice were
kept in individual cages to minimize licking of the wounds or ap-
plied agents. To determine the rate of closure, wounds were
traced onto clear plastic sheets on a daily basis and the area of the
wounds was quantitated by digitization of the wound tracings us-
ing a WACOM digitizing pad and Scan Analysis (Specom Re-
search, Ferguson, MO) software. These experiments were ap-
proved by the Institutional Animal Care and Use Committee
(New York University School of Medicine).
 
Excisional Wound Formation in Rats Rendered Diabetic.
 
Adult
(330–400 g) female Sprague-Dawley rats were given a single in-
traperitoneal injection of streptozotocin (60 mg/kg). Animals were
then rested for 8 d before excision of 2.0 cm wounds on the dor-
sum of the rats (15, 16). Wounds were treated daily with topical
application of 20 
 
m
 
l of either the adenosine agonist CGS-21680
(250 
 
m
 
g/ml) or vehicle (1.5%, wt/vol carboxymethylcellulose in
PBS). The animals were kept in individual cages to minimize the
licking of the wounds or applied agents. The rate of wound clo-
sure was determined as described above. Mean serum glucose, tested
on the final day of the experiment using the Easy Test
 
Ò
 
 Strips for
glucose with an Accu-Chek
 
Ò
 
 Easy
 
Ô
 
 
 
Monitor (Boehringer-Mann-
heim, Indianapolis, IN), was 156 
 
6
 
 18.5 mg/dl in the nondiabetic
rats as compared to 432 
 
6
 
 25 mg/dl in the diabetic rats. Seven
rats died after injection of streptozotocin but before excision of
the wounds and seven other diabetic rats died during the course
of these experiments (five control rats and two CGS-21680–
treated rats).
 
Histologic Analysis.
 
Some animals were killed on the stated
day by CO
 
2
 
 poisoning, and then wounds were excised and histo-
logic slides were made using standard methods. Slides, stained
with hematoxylin and eosin, were graded using a variation of the
scoring described by Tsuboi and Rifkin (17). In brief, reepithe-
lialization was measured on a score from 1 to 10 (1 
 
5
 
 no closure;
10 
 
5
 
 complete closure). Matrix density was scored from 1 to 4 (1 
 
5
 
edematous with little matrix; 2 
 
5
 
 a small amount of coarse ma-
trix; 3 
 
5
 
 a moderate amount of matrix; and 4 
 
5
 
 dense matrix).
Fibroblast infiltrate was scored from 1 to 4 (1 
 
5
 
 few fibroblasts; 2 
 
5
 
a moderate number of fibroblasts; 3 
 
5
 
 many cells; and 4 
 
5
 
 very
many cells). Inflammatory cells were graded from 1 to 4 (1 
 
5
 
very many cells; 2 
 
5
 
 many cells; 3 
 
5
 
 a moderate number of cells;
4 
 
5
 
 few cells). A maximum composite score of 22 can be ob-
tained. All slides were graded in a blinded fashion.
 
Results
 
Endothelial Cells and Fibroblasts Express Message for Multiple
Adenosine Receptors.
 
To establish the profile of adenosine
receptors expressed by fibroblasts and endothelial cells, we
determined whether mRNA for adenosine A
 
1
 
, A
 
2A
 
, A
 
2B
 
,
and A
 
3
 
 receptors was present in cultured dermal fibroblasts
and HUVEC by use of reverse transcriptase–PCR. As shown
in Fig. 1, message for A
 
2A
 
, A
 
2B
 
, and A
 
3
 
 receptors was present
in both fibroblasts and HUVEC. In contrast, message for
A
 
1
 
 receptors was expressed in HUVEC but not in fibro-
blasts. Results of other in vitro studies with these cells indi-
cated that occupancy of adenosine A
 
2
 
 receptors, both A
 
2A
 
and A
 
2B
 
 receptors, promoted migration of both fibroblasts
and HUVEC into an artificial in vitro wound by a cAMP-
dependent mechanism (data not shown). 
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Topical Application of an Adenosine A2A Receptor Agonist
Promotes Wound Closure In Vivo. The observation that both
HUVEC and dermal fibroblasts express mRNA for both A2A
and A2B receptors, the preliminary finding that adenosine
A2 receptor occupancy increases the rate of fibroblast mi-
gration, and the previous demonstration that agents binding
to adenosine A2 receptors may promote angiogenesis (3–6)
all suggested that an adenosine A2 receptor agonist might
accelerate wound healing in vivo. To test this hypothesis
we studied the effect of the topical application of CGS-
21680, the specific A2A agonist, on wound healing in
healthy, young (6–8-wk-old) BALB/c mice. As shown in
Fig. 2, wound closure was significantly more rapid in the
CGS-21680–treated mice than the mice treated with car-
rier alone (50% wound closure by day 2 versus by day 6;
P ,0.00001, n 5 10 wounds per group). Topical applica-
tion of the adenosine A2 receptor antagonist DMPX (2.5
mg/ml) did not affect wound healing itself, but completely
reversed the effects of CGS-21680 on the rate of wound
closure (Fig. 2 A). Similarly, the more selective A2A recep-
tor antagonist CSC also completely reversed the effect of
CGS-21680 on wound healing (Fig. 2 B). Upon histologic
examination of the wounds, fibroblast infiltration, matrix
density, and reepithelialization were markedly enhanced in
the CGS-21680–treated animals as compared to controls
(Fig. 3). Surprisingly, in contrast to the demonstrated anti-
inflammatory effects mediated by adenosine A2 receptor
occupancy (2), CGS-21680 did not affect the inflammatory
infiltrate in the wound until day 10 after wounding. The
change in inflammatory infiltrate observed so late in the
course of wound closure may have resulted from earlier
wound closure rather than any direct effect of CGS-21680
on inflammatory infiltrate in the wound. Topical applica-
tion of CGS-21680 to open wounds had no obvious toxic
effect on the mice.
Topical Application of an Adenosine A2A Receptor Agonist
Promotes Wound Closure in Diabetic Rats. Patients with di-
abetes mellitus suffer from impaired wound healing, and
poor wound healing is responsible for significant morbidity
and mortality in these patients. To determine whether an
adenosine A2A receptor agonist might be useful in the pro-
motion of wound healing in patients with diabetes, we
studied the effect of topical application of the adenosine re-
ceptor agonist CGS-21680 to full-thickness wounds in rats
rendered diabetic by a single injection of streptozotocin. As
expected, streptozotocin-treated rats had high serum glu-
cose concentrations (432 6 25 mg/dl in the diabetic rats
versus 156 6 18.5 mg/dl in the nondiabetic; P ,0.00001)
and the wounds of the diabetic animals healed more slowly
than those of the control animals (50% closure by day 9
versus by day 7, respectively; P ,0.0001; Fig. 4). As with
the normal young mice, topical application of CGS-21680
significantly promoted wound healing in the healthy non-
diabetic rats (50% closure by day 4; P ,0.0001, Fig. 4). More
importantly, application of CGS-21680 increased the rate
at which the diabetic animals closed their wounds (50%
closure by day 6, P ,0.0001, versus control diabetic rats,
Fig. 4) but did not affect the serum glucose concentration
(432 6 31 mg/dl versus 407 6 40 mg/dl in the control
and CGS-21680–treated diabetic rats, respectively; P 5
NS). Indeed, the rate of wound healing in CGS-21680–
treated diabetic animals was as good as or better than that in
the untreated controls (Fig. 4).
Discussion
The results reported here demonstrate that occupancy of
adenosine A2A receptors increases the rate at which wounds
Figure 1. Endothelial cells
(HUVEC) and a fibroblast cell
line (CCD-25sk) express mes-
sage for adenosine receptor sub-
types. RNA was isolated from
confluent monolayers of either
HUVEC or CCD-25sk cells, as described. cDNA was generated from the
isolated mRNA by reverse transcriptase and the message for the adeno-
sine receptors was amplified by antisense primers as described. Shown is
one of two experiments yielding similar results.
Figure 2. The effect of the adenosine A2A agonist CGS-21680 (250
mg/ml) on wound closure. (A) Wounds were excised on the dorsum of
mice and treated with carrier (1.5% methylcellulose), CGS-21680, the aden-
osine A2 antagonist DMPX (2.5 mg/ml), or their combination, as de-
scribed. Wounds were traced daily and the area was determined after
computer digitization of the wounds. (B) Wounds were excised on the
dorsum of mice and treated with carrier (1.5% methylcellulose), CGS-
21680, the adenosine A2A antagonist CSC (250 mg/ml), or their combi-
nation, as described. Each point represents the mean (6 SEM) of 10
wounds. Similar results were found in two other experiments.1618 Wound Healing Is Accelerated by Agonists of Adenosine A2 Receptors
heal in young, healthy mice and rats as well as in diabetic
rats. To our knowledge, this is the first demonstration that
a small nonpeptide agent, such as a purine nucleoside, pro-
motes wound healing. Equally striking is the finding that
this phenomenon occurs in normal, healthy animals, since
only a few of the known peptide growth factors that accel-
erate wound healing in sick animals also accelerate wound
closure in healthy animals (1).
Preliminary studies in our laboratory indicated that aden-
osine A2 receptor occupancy, both A2A and A2B, contrib-
utes to enhanced fibroblast and endothelial cell migration.
Signal transduction at adenosine A2A and A2B receptors pro-
ceeds, at least in part, via activation of heterotrimeric G pro-
teins leading to both cAMP-dependent and cAMP-indepen-
dent signaling events (2, 9, 18). Our studies demonstrate
that adenosine receptor occupancy promotes fibroblast and
endothelial cell migration by a cAMP- and PKA-dependent
pathway. In contrast, Sexl et al. have reported that adeno-
sine A2A receptor occupancy modulates endothelial cell
proliferation by a cAMP-independent mechanism (4, 19).
These disparate findings suggest that stimulation of migra-
tion and proliferation in endothelial cells are mediated by
different signal transduction pathways which diverge after
occupancy of adenosine A2A receptors. However, there is
no evidence that these divergent effects of adenosine recep-
tor occupancy occur in other cell types. Regardless of the
signal transduction pathway involved, our data clearly indi-
cate that agents that occupy adenosine A2 receptors, receptors
linked to GaS signal transduction proteins, promote wound
healing.
It is unlikely that an adenosine receptor-mediated in-
crease in fibroblast migration and angiogenesis is solely re-
sponsible for accelerating wound closure. Previous studies
have demonstrated that adenosine and its analogues, acting
at A2A receptors, increase secretion of vascular endothelial
growth factor in addition to promoting endothelial cell
proliferation and migration [3–6]. These observations sug-
gest that one mechanism by which adenosine receptor oc-
cupancy increases the rate of wound closure is by promot-
ing secretion of growth factors that act locally. Alternatively,
by inhibiting the secretion of a variety of inflammatory cy-
tokines (TNF-a, IL-6, IL-8) adenosine receptor occupancy
might diminish the secretion of agents that inhibit wound
healing (20–24). Another explanation for the effects of ade-
Figure 3. Histologic analysis
of wounds in control and CGS-
21680–treated mice. Wounds
were excised and mice were
treated with topical application
either of carrier or CGS-21680
in carrier. Analysis of fibroblast
density (A), matrix density (B),
epithelial closure (C), and in-
flammatory cell infiltrate (D) was
carried out blindly, as described.
Each point represents the mean
(6 SEM) of six wounds on three
mice.
Figure 4. The effect of the adenosine A2A agonist CGS-21680 on
wound closure in normal and diabetic rats. Animals received a single in-
jection of streptozotocin (60 mg/kg) followed 8 d later by excision of
three wounds (2 cm in diameter) on the dorsum of each rat. Wounds
were treated with carrier (1.5% methylcellulose/PBS, wt/vol) alone or
CGS-21680 (250 mg/ml) in carrier. The wounds were traced at the indi-
cated intervals and the area was determined after computer digitization of
the wounds. Each point represents the mean (6 SEM) of 9–21 wounds.1619 Montesinos et al. Brief Definitive Report
nosine receptor occupancy on wound healing is suggested
by the work of Boyle et al. who reported that adenosine A2
receptor occupancy specifically inhibits synthesis and secre-
tion of collagenase by synovial fibroblasts (14). Thus, di-
minished matrix degradation within the wound might also
enhance wound closure. Therefore, it is likely that there
are a number of adenosine-mediated effects that contribute
to the accelerated rate of wound closure and that are medi-
ated by ligation of adenosine receptors.
We conclude that adenosine A2 receptor agonists pro-
mote wound healing in normal and diabetic animals. This
is the first example of a member of the 7 transmembrane–
spanning, heterotrimeric G protein–associated family of re-
ceptors that, when occupied, promote wound healing by
itself. Moreover, unlike some growth factors, occupation of
adenosine A2A receptors promotes wound healing even in
young, healthy animals (1). The observation that this same
adenosine receptor agonist promotes wound healing in dia-
betic animals as well suggests an entirely novel approach for
development of agents that promote wound healing in both
normal individuals and individuals with impaired wound
healing.
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